~~What is Claimed is:~~

CLAIMS

~~1.~~ 1. A composition ~~comprising cyclobenzaprine, wherein the composition is suitable~~ for transmucosal absorption~~.~~

~~2. A composition comprising~~ comprising a pharmaceutically acceptable cyclobenzaprine salt and a basifying agent, wherein the composition comprises less than 9 mg of the cyclobenzaprine salt, and ~~a~~the cyclobenzaprine salt to basifying agent~~, wherein the composition~~ molar ratio is ~~suitable for transmucosal absorption~~between 1:0.5 to 1:6.

~~A~~

2. The composition of claim 1, comprising 0.1 mg to 5 mg of the pharmaceutically acceptable cyclobenzaprine salt.

3. The composition of claim 1, wherein the pharmaceutically acceptable cyclobenzaprine salt is present in an amount of less than or equal to 2.4 mg.

4. The composition ~~comprising amitriptyline~~of claim 1, wherein the pharmaceutically acceptable cyclobenzaprine salt is present in an amount of less than or equal to 4.8 mg.

~~3.~~ 5. The composition ~~is suitable for transmucosal absorption.~~of claim 1, wherein the pharmaceutically acceptable cyclobenzaprine salt is present in an amount of 2.8 mg.

~~4.~~ ~~A~~6. The composition ~~comprising amitriptyline and a basifying agent~~of claim 1, wherein the ~~composition~~pharmaceutically acceptable cyclobenzaprine salt is ~~suitable for transmucosal absorption~~present in an amount of 5.6 mg.

~~5.~~ 7. The composition of any one of claims ~~2 and 4~~1-6, wherein the basifying agent is selected from the group consisting of potassium dihydrogen phosphate, dipotassium hydrogen phosphate, tripotassium phosphate, sodium carbonate, sodium bicarbonate, calcium carbonate, calcium bicarbonate, TRIS buffer, sodium dihydrogen phosphate, disodium hydrogen phosphate, trisodium phosphate, potassium carbonate, potassium bicarbonate, potassium acetate, sodium acetate, dipotassium citrate, tripotassium citrate, disodium citrate and trisodium citrate.

~~6.~~ 8. The composition of any one of claims 1-~~5~~7, wherein the transmucosal absorption is oral absorption.

~~7.~~ 9. The composition of claim ~~6~~8, wherein the ~~composition~~oral absorption is ~~suitable for~~ sublingual ~~administration.~~absorption.

~~8.~~ 10. The composition of claim ~~7~~9, wherein the composition is ~~in a form~~ selected from the group consisting of a sublingual tablet, a sublingual film, a sublingual powder, and a sublingual spray solution.

~~9.~~ 11. The composition of ~~claim 6~~any one of claims 1-8, wherein the ~~composition~~transmucosal absorption is ~~suitable for~~ buccal ~~administration.~~absorption.

~~10.~~ 12. The composition of claim ~~9~~11, wherein the composition is ~~in a form~~ selected from the group consisting of a buccal tablet, a lozenge, a buccal powder, and a buccal spray solution.

~~11.~~ 13. The composition of any one of claims 1-~~5~~7, wherein the transmucosal absorption is intranasal absorption.

~~12.~~ 14. The composition of claim ~~11~~13, wherein the composition is ~~in a form of~~ a nasal spray solution.

~~13.~~ 15. The composition of any one of claims 1-~~5~~7, wherein the transmucosal absorption is pulmonary absorption.

~~14.~~ 16. The composition of claim ~~13~~15, wherein the composition is ~~in a form~~ selected from the group consisting of an aerosolized composition and an inhalable dry powder. ~~The~~

~~15.~~ 17. Use of a composition of any one of claims 1-~~14, characterized in that, when administered by~~ 7 in the manufacture of a medicament for transmucosal absorption~~, the cyclobenzaprine or amitriptyline has a dnC* of greater than or equal to 0.1 ± 25% x 10^{-7} mL^{-1} 15 minutes after administration.~~

~~16. The composition of any one of claims 1-15, characterized in that, when administered by transmucosal absorption, the cyclobenzaprine or amitriptyline has a dnC* of greater than or equal to 0.5 ± 25% x 10^{-7} mL^{-1} 30 minutes after administration.~~

~~17. The composition of any one of claims 1-16, characterized in that, when administered by transmucosal absorption, the cyclobenzaprine or amitriptyline has a dnC* of greater than or equal to 1.5 ± 25% x 10^{-7} mL^{-1} 45 minutes after administration.~~

18. The composition of any one of claims 1-17, characterized in that, when administered by transmucosal absorption, the cyclobenzaprine or amitriptyline has a dnC* of greater than or equal to 4.0 ± 25% x 10^{-7} mL^{-1} 1 hour after administration.

19. The composition of any one of claims 1-18, characterized in that, when administered by transmucosal absorption, the cyclobenzaprine or amitriptyline has a dnC* of greater than or equal to 5.2 ± 25% x 10^{-7} mL^{-1} 2 hours after administration .

20. The composition of any one of claims 1-19, characterized in that, when administered by transmucosal absorption, the cyclobenzaprine or amitriptyline has a dnC* of greater than or equal to 9.0 ± 25% x 10^{-6} mL^{-1} 3 hours after administration.

21. The composition of any one of claims 1-20, characterized in that, when administered by transmucosal absorption, the cyclobenzaprine or amitriptyline has a dnC* of less than or equal to 5.0 ± 25% x 10^{-7} mL^{-1} 10 hours after administration.

22. The composition of any one of claims 1-21, characterized in that, when administered by transmucosal absorption, the cyclobenzaprine or amitriptyline has a dnC* of less than or equal to 5.0 ± 25% x 10^{-7} mL^{-1} 12 hours after administration.

23. The composition of any one of claims 1-22, characterized in that, when administered by transmucosal absorption, the cyclobenzaprine or amitriptyline has a dnC* of less than or equal to 5.0 ± 25% x 10^{-7} mL^{-1} 14 hours after administration.

24. The composition of any one of claims 1-23, characterized in that, when administered by transmucosal absorption, the cyclobenzaprine or amitriptyline has a dnC* of less than or equal to 5.0 ± 25% x 10^{-7} mL^{-1} 16 hours after administration.

25. The composition of any one of claims 1-24, characterized in that, when administered by transmucosal absorption, the cyclobenzaprine or amitriptyline has a dnC* of less than or equal to 5.0 ± 25% x 10^{-7} mL^{-1} 18 hours after administration.

26. The composition of any one of claims 1-25, characterized in that, when administered by transmucosal absorption, the cyclobenzaprine or amitriptyline has a $dnAUC_{0\text{-}20min}$ of greater than or equal to 0.02 ± 25% x 10^{-6} hr mL^{-1}, a $dnAUC_{0\text{-}30min}$ of greater than or equal to 0.05 ± 25% x 10^{-6} hr mL^{-1}, a $dnAUC_{0\text{-}45min}$ of greater than or equal to 0.14 ± 25% x 10^{-6} hr mL^{-1}, a $dnAUC_{0\text{-}1h}$ of greater than or equal to 0.26 ± 25% x 10^{-6} hr mL^{-1}, a $dnAUC_{0\text{-}2h}$ of greater than or equal to 0.87 ± 25% x 10^{-6} hr mL^{-1}, or a $dnAUC_{0\text{-}2.5h}$ of greater than or equal to 1.23 ± 25% x 10^{-6} hr mL^{-1}.

27. The composition of any one of claims 1-26, characterized in that, when administered by transmucosal absorption, the cyclobenzaprine or amitriptyline has a dn$AUC_{0-\infty h}$ of greater than or equal to 20 mL^{-1} hr^{-1}.

28. The composition of any one of claims 1-27, characterized in that, when administered by transmucosal absorption, the cyclobenzaprine or amitriptyline has a dnC_{max}* of greater than or equal to 1.0 ± 25% x 10^{-6} mL^{-1}.

29. The composition of any one of claims 1-28, characterized in that, when administered by transmucosal absorption, the cyclobenzaprine or amitriptyline has a plasma concentration of 50% or less of the C_{max} 4 hours after administration.

30. The composition of any one of claims 1-29, characterized in that, when administered by transmucosal absorption, the cyclobenzaprine or amitriptyline has a plasma concentration of 50% or less of the C_{max} 6 hours after administration.

31. The composition of any one of claims 1-30, characterized in that, when administered by transmucosal absorption, the cyclobenzaprine or amitriptyline has a plasma concentration of 50% or less of the C_{max} 8 hours after administration.

32. The composition of any one of claims 1-31, characterized in that, when administered by transmucosal absorption, the cyclobenzaprine or amitriptyline has a plasma concentration of 50% or less of the C_{max} 12 hours after administration.

33. The composition of any one of claims 1-32, wherein the cyclobenzaprine is present in an amount from 0.1 mg to 10 mg.

34. The composition of claim 33, wherein the cyclobenzaprine is present in an amount from 0.1 mg to 5 mg.

35. The composition of claim 34, wherein the cyclobenzaprine is present in an amount of about 2.4 mg.

36. The composition of claim 34, wherein the cyclobenzaprine is present in an amount of less than about 2.4 mg.

37. The composition of claim 34, wherein the cyclobenzaprine is present in an amount of about 4.8 mg.

38. The composition of claim 34, wherein the cyclobenzaprine is present in an amount of less than about 4.8 mg.

~~39. The composition of any one of claims 1-38, characterized in that, when administered by transmucosal absorption, the composition affords a C_{max} of cyclobenzaprine greater than or equal to 10 ng/mL.~~

~~40. The composition of claim 39, characterized in that, when administered by transmucosal absorption, the composition affords a C_{max} of cyclobenzaprine greater than or equal to 15 ng/mL.~~

~~41. The composition of claim 40, characterized in that, when administered by transmucosal absorption, the composition affords a C_{max} of cyclobenzaprine greater than or equal to 20 ng/mL.~~

~~42. The composition of claim 41, characterized in that, when administered by transmucosal absorption, the composition affords a C_{max} of cyclobenzaprine greater than or equal to 25 ng/mL.~~

~~43. The composition of claim 42, characterized in that, when administered by transmucosal absorption, the composition affords a C_{max} of cyclobenzaprine greater than or equal to 30 ng/mL.~~

~~44. The composition of any one of claims 1-43, characterized in that, when administered by transmucosal absorption, the composition affords a C_{max} of cyclobenzaprine greater than or equal to 10 ng/mL above the baseline level of cyclobenzaprine in the individual immediately prior to administration.~~

~~45. The composition of claim 44, characterized in that, when administered by transmucosal absorption, the composition affords a C_{max} of cyclobenzaprine greater than or equal to 15 ng/mL above the baseline level of cyclobenzaprine in the individual immediately prior to administration.~~

~~46. The composition of claim 45, characterized in that, when administered by transmucosal absorption, the composition affords a C_{max} of cyclobenzaprine greater than or equal to 20 ng/mL above the baseline level of cyclobenzaprine in the individual immediately prior to administration.~~

~~47. The composition of claim 46, characterized in that, when administered by transmucosal absorption, the composition affords a C_{max} of cyclobenzaprine greater than or equal to 25 ng/mL above the baseline level of cyclobenzaprine in the individual immediately prior to administration.~~

48. The composition of claim 47, characterized in that, when administered by transmucosal absorption, the composition affords a C_{max} of cyclobenzaprine greater than or equal to 30 ng/mL above the baseline level of cyclobenzaprine in the individual immediately prior to administration.

49. The composition of any one of claims 1-48, characterized in that, when administered by transmucosal absorption, the composition affords a t_{max} of cyclobenzaprine of less than 4 hours.

50. The composition of claim 49, characterized in that, when administered by transmucosal absorption, the composition affords a t_{max} of cyclobenzaprine of less than 3 hours.

51. The composition of claim 50, characterized in that, when administered by transmucosal absorption, the composition affords a t_{max} of cyclobenzaprine of less than 2 hours.

52. The composition of claim 51, characterized in that, when administered by transmucosal absorption, the composition affords a t_{max} of cyclobenzaprine of less than 1 hour.

53. The composition of claim 52, characterized in that, when administered by transmucosal absorption, the composition affords a t_{max} of cyclobenzaprine of less than 45 minutes.

54. The composition of claim 53, characterized in that, when administered by transmucosal absorption, the composition affords a t_{max} of cyclobenzaprine of less than 30 minutes.

55. The composition of claim 54, characterized in that, when administered by transmucosal absorption, the composition affords a t_{max} of cyclobenzaprine of less than 15 minutes.

56. The composition of any one of claims 1-55, characterized in that, when administered by transmucosal absorption, the composition affords a plasma level of cyclobenzaprine that decreases by at least 50% of the C_{max} by 8 hours after administration.

57. The composition of claim 56, characterized in that, when administered by transmucosal absorption, the composition affords a plasma level of cyclobenzaprine that decreases by at least 60% of the C_{max} by 8 hours after administration.

58. The composition of claim 57, characterized in that, when administered by transmucosal absorption, the composition affords a plasma level of cyclobenzaprine that decreases by at least 70% of the C_{max} by 8 hours after administration.

~~59. The composition of claim 58, characterized in that, when administered by transmucosal absorption, the composition affords a plasma level of cyclobenzaprine that decreases by at least 80% of the C_{max} by 8 hours after administration.~~

~~60. The composition of claim 59, characterized in that, when administered by transmucosal absorption, the composition affords a plasma level of cyclobenzaprine that decreases by at least 90% of the C_{max} by 8 hours after administration.~~

~~61. The composition of claim 60, characterized in that, when administered by transmucosal absorption, the composition affords a plasma level of cyclobenzaprine that decreases by at least 95% of the C_{max} by 8 hours after administration.~~

~~62. A method~~ for treating a disease or condition in an individual in need thereof~~ comprising administering a composition of any one of claims 1-61 by transmucosal absorption.~~

~~63. The method of claim 62~~, wherein the disease or condition is post-traumatic stress disorder (PTSD~~).~~

~~64. The method of claim 63, wherein administration of the composition treats the development of PTSD following a traumatic event.~~

~~65. The method of claim 63, wherein administration of the composition treats the initiation of PTSD following a traumatic event.~~

~~66. The method of claim 63, wherein administration of the composition treats the consolidation of PTSD following a traumatic event.~~

~~67. The method of claim 63, wherein administration of the composition treats the perpetuation of PTSD following a traumatic event.~~

~~68. The method of claim 62, wherein the disease or condition is selected from the group consisting of~~), fibromyalgia, depression, traumatic brain injury, sleep disorder, non-restorative sleep, chronic pain, muscle spasm, ~~and~~or anxiety disorder.

~~69. The method of any one of claims 62-68, wherein the basifying agent is selected from the group consisting of potassium dihydrogen phosphate, dipotassium hydrogen phosphate, tripotassium phosphate, sodium carbonate, sodium bicarbonate, calcium carbonate, calcium bicarbonate, TRIS buffer, sodium dihydrogen phosphate, disodium hydrogen phosphate, trisodium phosphate, potassium carbonate, potassium bicarbonate, potassium acetate, sodium acetate, dipotassium citrate, tripotassium citrate, disodium citrate and trisodium citrate.~~

18. The use of claim 17, wherein the disease or condition is post-traumatic stress disorder (PTSD).

19. The ~~method~~use of claim 18, wherein the disease or condition is the development, initiation, consolidation, or perpetuation of PTSD following a traumatic event.

~~70.~~ 20. The use of any one of claims ~~62-69~~17-19, wherein the ~~oral~~transmucosal absorption is sublingual absorption.

~~71.~~ 21. The ~~method~~use of claim ~~70~~20, wherein the ~~composition~~medicament is ~~in a form~~ selected from the group consisting of a sublingual tablet, a sublingual film, a sublingual powder, and a sublingual spray solution.

~~72.~~ 22. The ~~method~~use of any one of claims ~~62-69~~17-19, wherein the ~~oral~~transmucosal absorption is buccal absorption.

~~73.~~ 23. The ~~method~~use of claim ~~72~~22, wherein the ~~composition~~medicament is selected from the group consisting of a buccal tablet, a lozenge, a buccal powder, and a buccal spray solution.

~~74.~~ 24. The ~~method~~use of any one of claims ~~62-73~~17-19, wherein the transmucosal absorption is intranasal absorption.

~~75.~~ 25. The ~~method~~use of claim ~~74~~24, wherein the ~~composition~~medicament is ~~in a form of~~ a nasal spray solution.

~~76.~~ 26. The ~~method~~use of any one of claims ~~62-73~~17-19, wherein the transmucosal absorption is pulmonary absorption.

~~77.~~ 27. The ~~method~~use of claim ~~76~~26, wherein the ~~composition~~medicament is ~~in a form~~ selected from the group consisting of an aerosolized composition and an inhalable dry powder.

~~78. The method of any one of claims 62-77, wherein the cyclobenzaprine or amitriptyline has a dnC* of greater than or equal to 1.0 ± 25% x 10^{-7} mL^{-1} 20 minutes after administration.~~

79. The method of any one of claims 62-78, wherein the cyclobenzaprine or amitriptyline has a dnC* of greater than or equal to 2.5 ± 25% x 10^{-7} mL^{-1} 30 minutes after administration.

80. The method of any one of claims 62-79, wherein the cyclobenzaprine or amitriptyline has a dnC* of greater than or equal to 3.0 ± 25% x 10^{-7} mL^{-1} 45 minutes after administration.

81. The method of any one of claims 62-80, wherein the cyclobenzaprine or amitriptyline has a dnC* of greater than or equal to 4.2 ± 25% x 10^{-7} mL^{-1} 1 hour after administration.

82. The method of any one of claims 62-81, wherein the cyclobenzaprine or amitriptyline has a dnC* of greater than or equal to 6.0 ± 25% x 10^{-7} mL^{-1} 2 hours after administration.

83. The method of any one of claims 62-82, wherein the cyclobenzaprine or amitriptyline has a dnC* of greater than or equal to 7.0 ± 25% x 10^{-7} mL^{-1} 3 hours after administration.

84. The method of any one of claims 62-83, wherein the cyclobenzaprine or amitriptyline has a dnC* of greater than or equal to 8.0 ± 25% x 10^{-7} mL^{-1} 3.3 hours after administration.

85. The method of any one of claims 62-84, wherein the cyclobenzaprine or amitriptyline has a dnC* of less than or equal to 5.0 ± 25% x 10^{-7} mL^{-1} 12 hours after administration.

86. The method of any one of claims 62-85, wherein the cyclobenzaprine or amitriptyline has a dnC* of less than or equal to 5.0 ± 25% x 10^{-7} mL^{-1} 14 hours after administration.

87. The method of any one of claims 62-86, wherein the cyclobenzaprine or amitriptyline has a dnC* of less than or equal to 5.0 ± 25% x 10^{-7} mL^{-1} 16 hours after administration.

88. The method of any one of claims 62-87, wherein the cyclobenzaprine or amitriptyline has a dnC* of less than or equal to 5.0 ± 25% x 10^{-7} mL^{-1} 18 hours after administration.

89. The method of any one of claims 62-88, wherein the cyclobenzaprine or amitriptyline has a $dnAUC_{0\text{-}20min}$ of greater than or equal to 0.02 ± 25% x 10^{-6} hr mL^{-1}, a $dnAUC_{0\text{-}30min}$ of greater than or equal to 0.05 ± 25% x 10^{-6} hr mL^{-1}, a $dnAUC_{0\text{-}45min}$ of greater than or equal to 0.14 ± 25% x 10^{-6} hr mL^{-1}, a $dnAUC_{0\text{-}1h}$ of greater than or equal to 0.26 ± 25% x 10^{-6} hr mL^{-1}, a

~~$dnAUC_{0\text{-}2h}$ of greater than or equal to 0.87 ± 25% x 10^{-6} hr mL^{-1}, or a $dnAUC_{0\text{-}2.5h}$ of greater than or equal to 1.23 ± 25% x 10^{-6} hr mL^{-11}.~~

~~90. The method of any one of claims 62-89, wherein the cyclobenzaprine or amitriptyline has a $dnAUC_{0\text{-}\infty h}$ of greater than or equal to 20 mL^{-1} hr^{-1}.~~

~~91. The method of any one of claims 62-90, wherein the cyclobenzaprine or amitriptyline has a dnC_{max}* of greater than or equal to 1.0 ± 25% x 10^{-6} mL^{-1}.~~

~~92. The method of any one of claims 62-91, wherein the cyclobenzaprine or amitriptyline has a plasma concentration of 50% or less of the C_{max} 4 hours after administration.~~

~~93. The method of any one of claims 62-92, wherein the cyclobenzaprine or amitriptyline has a plasma concentration of 50% or less of the C_{max} 6 hours after administration.~~

~~94. The method of any one of claims 62-93, wherein the cyclobenzaprine or amitriptyline has a plasma concentration of 50% or less of the C_{max} 8 hours after administration.~~

~~95. The method of any one of claims 62-94, wherein the cyclobenzaprine or amitriptyline has a plasma concentration of 50% or less of the C_{max} 12 hours after administration.~~

~~96. The method of any one of claims 62-95, wherein the cyclobenzaprine is present in the composition in an amount from 0.1 mg to 10 mg.~~

~~97. The method of claim 96, wherein the cyclobenzaprine is present in the composition in an amount from 0.1 mg to 5 mg.~~

~~98. The method of claim 97, wherein the cyclobenzaprine is present in the composition in an amount of about 2.4 mg.~~

~~99. The method of claim 98, wherein the cyclobenzaprine is present in an amount of less than about 2.4 mg.~~

~~100. The method of claim 99, wherein the cyclobenzaprine is present in an amount of about 4.8 mg.~~

~~101. The method of claim 100, wherein the cyclobenzaprine is present in an amount of less than about 4.8 mg.~~

~~102. The method of any one of claims 62-101, wherein the composition affords a C_{max} of cyclobenzaprine greater than or equal to 10 ng/mL.~~

~~103. The method of claim 102, wherein the composition affords a C_{max} of cyclobenzaprine greater than or equal to 15 ng/mL.~~

~~104. The method of claim 103, wherein the composition affords a C_{max} of cyclobenzaprine greater than or equal to 20 ng/mL.~~

~~105. The method of claim 104, wherein the composition affords a C_{max} of cyclobenzaprine greater than or equal to 25 ng/mL.~~

~~106. The method of claim 105, wherein the composition affords a C_{max} of cyclobenzaprine greater than or equal to 30 ng/mL.~~

~~107. The method of any one of claims 62-106, wherein the composition affords a C_{max} of cyclobenzaprine greater than or equal to 10 ng/mL above the baseline level of cyclobenzaprine in the individual immediately prior to administration.~~

~~108. The method of claim 107, wherein the composition affords a C_{max} of cyclobenzaprine greater than or equal to 15 ng/mL above the baseline level of cyclobenzaprine in the individual immediately prior to administration.~~

~~109. The method of claim 108, wherein the composition affords a C_{max} of cyclobenzaprine greater than or equal to 20 ng/mL above the baseline level of cyclobenzaprine in the individual immediately prior to administration.~~

~~110. The method of claim 109, wherein the composition affords a C_{max} of cyclobenzaprine greater than or equal to 25 ng/mL above the baseline level of cyclobenzaprine in the individual immediately prior to administration.~~

~~111. The method of claim 110, wherein the composition affords a C_{max} of cyclobenzaprine greater than or equal to 30 ng/mL above the baseline level of cyclobenzaprine in the individual immediately prior to administration.~~

~~112. The method of any one of claims 62-111, wherein the composition affords a t_{max} of cyclobenzaprine of less than 4 hours.~~

~~113. The method of claim 112, wherein the composition affords a t_{max} of cyclobenzaprine of less than 3 hours.~~

~~114. The method of claim 113, wherein the composition affords a t_{max} of cyclobenzaprine of less than 2 hours.~~

115. The method of claim 114, wherein the composition affords a t_{max} of cyclobenzaprine of less than 1 hour.

116. The method of claim 115, wherein the composition affords a t_{max} of cyclobenzaprine of less than 45 minutes.

117. The method of claim 116, wherein the composition affords a t_{max} of cyclobenzaprine of less than 30 minutes.

118. The method of claim 117, wherein the composition affords a t_{max} of cyclobenzaprine of less than 15 minutes.

119. The method of any one of claims 62-118, wherein the composition affords a plasma level of cyclobenzaprine that decreases by at least 50% of the C_{max} by 8 hours after administration.

120. The method of claim 119, wherein the composition affords a plasma level of cyclobenzaprine that decreases by at least 60% of the C_{max} by 8 hours after administration.

121. The method of claim 120, wherein the composition affords a plasma level of cyclobenzaprine that decreases by at least 70% of the C_{max} by 8 hours after administration.

122. The method of claim 121, wherein the composition affords a plasma level of cyclobenzaprine that decreases by at least 80% of the C_{max} by 8 hours after administration.

123. The method of claim 122, wherein the composition affords a plasma level of cyclobenzaprine that decreases by at least 90% of the C_{max} by 8 hours after administration.

124. The method of claim 123, wherein the composition affords a plasma level of cyclobenzaprine that decreases by at least 95% of the C_{max} by 8 hours after administration.

125. A composition comprising cyclobenzaprine for transmucosal administration comprising from about 2 to about 20 mg of cyclobenzaprine or a salt thereof, said formulation affording a C_{max} of cyclobenzaprine from about 20 to about 200 ng/mL from about 0.0.05 to about 2.5 hours after administration, and a minimum cyclobenzaprine plasma concentration from about 1 to about 5 ng/mL from about 22 to about 26 hours after administration, wherein the composition is administered for four days or more of daily administration.

126. A method for reducing the symptoms of fibromyalgia in a human patient, comprising administering a transmucosal dosage formulation comprising from about 2 to about 20 mg of cyclobenzaprine or a salt thereof, said formulation affording a C_{max} of cyclobenzaprine from about

20 to about 200 ng/mL from about 0.05 to about 2.5 hours after administration, and a minimum plasma concentration from about 1 to about 5 ng/mL from about 22 to about 26 hours after administration, wherein the composition is administered for four days or more of daily administration, and wherein the composition is administered within two hours of sleep.

127. A composition comprising amitriptyline for transmucosal administration comprising from about 2 to about 25 mg of amitriptyline or a salt thereof, said formulation affording a C_{max} of amitriptyline from about 20 to about 200 ng/mL from about 0.05 to about 2.5 hours after administration, and a minimum amitriptyline plasma concentration from about 1 to about 5 ng/mL from about 22 to about 26 hours after administration, wherein the composition is administered for four days or more of daily administration.

128. A method for reducing the symptoms of fibromyalgia in a human patient, comprising administering a transmucosal dosage formulation comprising from about 2 to about 25 mg of amitriptyline or a salt thereof, said formulation affording a C_{max} of amitriptyline from about 20 to about 200 ng/mL from about 0.05 to about 2.5 hours after administration, and a minimum plasma concentration from about 1 to about 5 ng/mL from about 22 to about 26 hours after administration, wherein the composition is administered for four days or more of daily administration, and wherein the composition is administered within two hours of sleep.

129. The composition of any one of claims 1-14, characterized in that, when administered by transmucosal absorption, the cyclobenzaprine or amitriptyline has a dn$C$* of greater than or equal to 1.0 ± 25% x 10^{-7} mL^{-1} 20 minutes after administration .

130. The composition of any one of claims 1-14, characterized in that, when administered by transmucosal absorption, the cyclobenzaprine or amitriptyline has a dn$C$* of greater than or equal to 157.60 x 10^{-9} mL^{-1} 20 minutes after administration.

131. The composition of any one of claims 1-14, characterized in that, when administered by transmucosal absorption, the cyclobenzaprine or amitriptyline has a dn$C$* of 2.5 ± 25% x 10^{-7} 30 minutes after administration.

132. The composition of any one of claims 1-14, characterized in that, when administered by transmucosal absorption, the cyclobenzaprine or amitriptyline has a dn$C$* of greater than or equal to 3.0 ± 25% x 10^{-7} mL^{-1} 45 minutes after administration.

133. The composition of any one of claims 1-14, characterized in that, when administered by transmucosal absorption, the cyclobenzaprine or amitriptyline has a dn$C$* of greater than or equal to 4.2 ± 25% x 10^{-7} mL^{-1} 60 minutes after administration.

134. The composition of any one of claims 1-14, characterized in that, when administered by transmucosal absorption, the cyclobenzaprine or amitriptyline has a dnC* of greater than or equal to 6.0 ± 25% x 10^{-7} mL^{-1} 2 hours after administration.

135. The composition of any one of claims 1-14, characterized in that, when administered by transmucosal absorption, the cyclobenzaprine or amitriptyline has a dnC* of greater than or equal to 6.5 ± 25% x 10^{-7} mL^{-1} 2.5 hours after administration.

136. The composition of any one of claims 1-14, characterized in that, when administered by transmucosal absorption, the cyclobenzaprine or amitriptyline has a dnC* of greater than or equal to 7.0 ± 25% x 10^{-7} mL^{-1} 3 hours after administration.

137. The composition of any one of claims 1-32, wherein the cyclobenzaprine is present in an amount of 2.8 mg.

138. The composition of any one of claims 1-32, wherein the cyclobenzaprine is present in an amount of 5.6 mg.

139. The composition of any one of claims 1-32, wherein the cyclobenzaprine is present in an amount of less than about 9 mg.

140. The method of any one of claims 62-77, wherein the cyclobenzaprine or amitriptyline has a dnC* of greater than or equal to 1.0 ± 25% x 10^{-7} mL^{-1} 20 minutes after administration.

141. The method of any one of claims 62-77, wherein the cyclobenzaprine or amitriptyline has a dnC* of greater than or equal to 2.5 ± 25% x 10^{-7} 30 minutes after administration.

142. The method of any one of claims 62-77, wherein the cyclobenzaprine or amitriptyline has a dnC* of greater than or equal to 3.0 ± 25% x 10^{-7} 45 minutes after administration.

143. The method of any one of claims 62-77, wherein the cyclobenzaprine or amitriptyline has a dnC* of greater than or equal to 4.2 ± 25% x 10^{-7} 1 hour after administration.

144. The method of any one of claims 62-77, wherein the cyclobenzaprine or amitriptyline has a dnC* of greater than or equal to 6.0 ± 25% x 10^{-7} mL^{-1} 2 hours after administration.

145. The method of any one of claims 62-77, wherein the cyclobenzaprine or amitriptyline has a dnC* of greater than or equal to 6.5 ± 25% x 10^{-7} mL^{-1} 2.5 hours after administration.

~~146. The method of any one of claims 62-77, wherein the cyclobenzaprine or amitriptyline has a dnC* of greater than or equal to 727.67 ± 25% x 10^{-9} mL^{-1} 2.5 hours after administration.~~

~~147. The method of any one of claims 62-77, wherein the cyclobenzaprine or amitriptyline has a dnC* of greater than or equal to 7.0 ± 25% x 10^{-7} mL^{-1} 3 hours after administration.~~

~~148. The composition of any one of claims 1-38, characterized in that, when administered by transmucosal absorption, the composition affords a C_{max} of cyclobenzaprine greater than or equal to 2 ng/mL.~~

~~149. The composition of any one of claims 1-43, characterized in that, when administered by transmucosal absorption, the composition affords a C_{max} of cyclobenzaprine greater than or equal to 2 ng/mL above the baseline level of cyclobenzaprine in the individual immediately prior to administration.~~